What is Outpace Bio?
Outpace Bio operates at the intersection of synthetic biology and oncology, focusing on the development of smart cell therapies. The company utilizes sophisticated protein design to engineer T cells that are more resilient, specific, and effective within the complex microenvironment of solid tumors. By addressing the fundamental limitations of current cell therapy modalities, Outpace Bio is carving out a significant niche in the competitive landscape of personalized medicine. Their platform is designed to enhance the therapeutic index of existing treatments, offering a scalable solution to some of the most challenging problems in modern immunology and cancer research.
How much funding has Outpace Bio raised?
Outpace Bio has raised a total of $174M across 2 funding rounds:
Series A
$30M
Series B
$144M
Series A (2021): $30M with participation from Mubadala, Civilization Ventures, Lyell Immunopharma, WRF Capital, Artis Ventures Management Iii, Abstract Ventures, Sahsen Ventures, and Playground
Series B (2024): $144M led by WRF Capital, RA Capital Management, and Qatar Investment Authority
Key Investors in Outpace Bio
WRF Capital
Washington Research Foundation (WRF) is a leading early-stage investor focused on transforming innovative ideas into successful businesses in Washington, specializing in life sciences and technology commercialization.
RA Capital Management
RA Capital Management is a multi-stage investment manager focused on evidence-based investing in public and private healthcare and life science companies, utilizing their internal think tank, TechAtlas, to guide strategy.
Qatar Investment Authority
Qatar Investment Authority is the sovereign wealth fund of the State of Qatar, managing global financial assets to diversify the national economy and support long-term strategic development.
What's next for Outpace Bio?
With the successful closure of its latest funding round, Outpace Bio is poised to transition from a research-heavy entity into a more mature clinical-stage organization. The strategic focus will likely shift toward the expansion of its internal pipeline and the potential for collaborative partnerships to validate its protein design technologies in human trials. As the company scales, it will continue to leverage its deep expertise in synthetic biology to refine its therapeutic candidates, aiming to deliver curative outcomes for patients with solid tumors. The ongoing support from a diverse syndicate of global investors provides the necessary runway to navigate the rigorous regulatory and clinical milestones ahead, solidifying the company's role as a pivotal player in the future of precision oncology.
See full Outpace Bio company page
